Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD

Dirkje S Postma, Nicolas Roche, Gene Colice, Elliot Israel, Richard J Martin, Willem Mc van Aalderen, Jonathan Grigg, Anne Burden, Elizabeth V Hillyer, Julie von Ziegenweidt, Gokul Gopalan, David Price

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)
3 Downloads (Pure)

Abstract

PURPOSE: Small airway changes and dysfunction contribute importantly to airway obstruction in chronic obstructive pulmonary disease (COPD), which is currently treated with inhaled corticosteroids (ICS) and long-acting bronchodilators at Global initiative for Obstructive Lung Disease (GOLD) grades 2-4. This retrospective matched cohort analysis compared effectiveness of a representative small-particle ICS (extrafine beclomethasone) and larger-particle ICS (fluticasone) in primary care patients with COPD.

PATIENTS AND METHODS: Smokers and ex-smokers with COPD ≥40 years old initiating or stepping-up their dose of extrafine beclomethasone or fluticasone were matched 1:1 for demographic characteristics, index prescription year, concomitant therapies, and disease severity during 1 baseline year. During 2 subsequent years, we evaluated treatment change and COPD exacerbations, defined as emergency care/hospitalization for COPD, acute oral corticosteroids, or antibiotics for lower respiratory tract infection.

RESULTS: Mean patient age was 67 years, 57%-60% being male. For both initiation (n=334:334) and step-up (n=189:189) patients, exacerbation rates were comparable between extrafine beclomethasone and fluticasone cohorts during the 2 year outcome period. Odds of treatment stability (no exacerbation or treatment change) were significantly greater for patients initiating extrafine beclomethasone compared with fluticasone (adjusted odds ratio 2.50; 95% confidence interval, 1.32-4.73). Median ICS dose exposure during 2 outcome years was significantly lower (P<0.001) for extrafine beclomethasone than fluticasone cohorts (315 μg/day versus 436 μg/day for initiation, 438 μg/day versus 534 μg/day for step-up patients).

CONCLUSION: We observed that small-particle ICS at significantly lower doses had comparable effects on exacerbation rates as larger-particle ICS at higher doses, whereas initiation of small-particle ICS was associated with better odds of treatment stability during 2-years' follow-up.

Original languageEnglish
Pages (from-to)1163-1186
Number of pages24
JournalInternational journal of chronic obstructive pulmonary disease
Volume9
DOIs
Publication statusPublished - 17 Oct 2014

Keywords

  • COPD exacerbation
  • extrafine particle
  • matched cohort analysis
  • real life
  • small airways

Fingerprint

Dive into the research topics of 'Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD'. Together they form a unique fingerprint.

Cite this